Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2014
Can patient navigation improve receipt of recommended breast cancer care? Evidence from the National Patient Navigation Research Program.
Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 97 citations in OpenAlex.
- Patient Navigation in Cancer Treatment: A Systematic Review.Current oncology reports · 2024Pooled it
- Mapping the Postpartum Experience Through Obstetric Patient Navigation for Low-Income Individuals.Journal of women's health (2002) · 2024Trial
- Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room to Grow.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Patient Navigation in Medically Underserved Areas study design: A trial with implications for efficacy, effect modification, and full continuum assessment.Contemporary clinical trials · 2017Trial
- Catalyzing Navigation for Breast Cancer Survivorship (CaNBCS) in Safety-Net Settings: A Mixed Methods Study.Cancer control : journal of the Moffitt Cancer CenterTrial
- Acute Care Events During Systemic Cancer Treatment: Moving From Risk Prediction to Clinical Decision Support Using a Two-Model Approach.JCO oncology practice · 2026Article
- "Pink is my least favorite color": experiences of sexual minority women and partners navigating breast cancer.Journal of psychosocial oncology · 2026Article
- Principles to promote social equality across the cancer trajectory: A group concept mapping study.Acta oncologica (Stockholm, Sweden) · 2025Article
- Racial Disparities in the Prescribing of Guideline-Recommended Medications for Metastatic Prostate Cancer: A Retrospective Cohort Study.Prostate cancer · 2025Article
- Underserved Patient Populations With Metastatic Breast Cancer: A Review of Progress and Remaining Challenges.The breast journal · 2025Review
- Association Between Racial and Socioeconomic Disparities and Hospital Performance in Treatment and Outcomes for Patients with Colon Cancer.Annals of surgical oncology · 2024Article
- Importance of Diversity, Equity, and Inclusion in the Hepatopancreatobiliary Workforce.Cancers · 2024Review
- Navigation programs to support community-dwelling individuals with life-limiting illness: determinants of implementation.BMC health services research · 2024Article
- Patient Navigation for Timely, Guideline-Adherent Adjuvant Therapy for Head and Neck Cancer: A National Landscape Analysis.Journal of the National Comprehensive Cancer Network : JNCCN · 2023Article
- How do navigation programs address the needs of those living in the community with advanced, life-limiting Illness? A realist evaluation of programs in Canada.BMC palliative care · 2023Article
- Lessons to inform interventions to reduce racial and ethnic health disparities within hematologic malignancies.Cancer causes & control : CCC · 2023Review
- The Colocation Model in Community Cancer Care: A Description of Patient Clinical and Demographic Attributes and Referral Pathways.JCO oncology practice · 2023Review
- The impact of substance use on health care utilization, treatment, and outcomes in patients with non-small cell lung cancer.Journal of thoracic disease · 2022Article
- Assessment of patient navigation programs for breast cancer patients across the city of Boston.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Systematic Patient Navigation Strategies to Scale Breast Cancer Disparity Reduction by Improved Cancer Prevention and Care Delivery Processes.JCO oncology practice · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Naomi Y KoNaomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO. naomi.ko@bmc.org.
Julie S DarnellNaomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO.
Elizabeth CalhounNaomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO.
Karen M FreundNaomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO.
Kristin J WellsNaomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO.
Charles L ShapiroNaomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO.
Donald J DudleyNaomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO.
Steven R PatiernoNaomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO.
Kevin FiscellaNaomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO.
Peter RaichNaomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO.
Tracy A BattagliaNaomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO.
George Washington University · US
Funding
Chicago Cancer Navigation ProjectU01CA116875 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ROSEN, STEVEN TERRY · 2005 to 2011
$4.5MRCT of Primary Care-based Patient Navigation-ActivationU01CA116924 · NCI · UNIVERSITY OF ROCHESTER · PI FISCELLA, KEVIN ANTHONY · 2005 to 2011
$4.4M"Patient Navigation in the SafetyNet: CONNECTeDD"U01CA116892 · NCI · BOSTON MEDICAL CENTER · PI FREUND, KAREN · 2005 to 2010
$4.3MDC City-wide Patient Navigation Research ProgramU01CA116937 · NCI · GEORGE WASHINGTON UNIVERSITY · PI PATIERNO, STEVEN R · 2005 to 2011
$4.1MBehavioral Oncology Education & Career DevelopmentR25CA090314 · NCI · H. LEE MOFFITT CANCER CTR &RES INST · PI BRANDON, THOMAS H · 2003 to 2018
$4.0MImproving Patient Outcomes Through System NavigationU01CA116903 · NCI · DENVER HEALTH AND HOSPITAL AUTHORITY · PI RAICH, PETER CHRISTIAN · 2005 to 2011
$3.8MPatient Navigation Research ProgramU01CA116885 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI DUDLEY, DONALD J · 2005 to 2010
$3.3MPatient Navigator ProgramU01CA117281 · NCI · H. LEE MOFFITT CANCER CTR &RES INST · PI ROETZHEIM, RICHARD G · 2005 to 2009
$3.1MNorthwest Tribal Cancer Navigator ProgramU01CA116925 · NCI · NORTHWEST PORTLAND AREA INDIAN HLTH BD · PI WARREN-MEARS, VICTORIA ANN · 2005 to 2009
$3.0MNCI NIH HHS 01CA116937NCI NIH HHS R25 CA090314NCI NIH HHS R25CA090314NCI NIH HHS U01 CA116875NCI NIH HHS U01CA116875NCI NIH HHS U01 CA116885NCI NIH HHS U01CA116885NCI NIH HHS U01 CA116892NCI NIH HHS U01CA116892NCI NIH HHS U01 CA116903NCI NIH HHS U01CA116903NCI NIH HHS U01 CA116924NCI NIH HHS U01CA116924NCI NIH HHS U01 CA116925NCI NIH HHS U01CA116925NCI NIH HHS U01 CA116937NCI NIH HHS U01 CA117281NCI NIH HHS U01CA117281
Abstract
purposePoor and underserved women face barriers in receiving timely and appropriate breast cancer care. Patient navigators help individuals overcome these barriers, but little is known about whether patient navigation improves quality of care. The purpose of this study is to examine whether navigated women with breast cancer are more likely to receive recommended standard breast cancer care. PATIENTS AND
methodsWomen with breast cancer who participated in the national Patient Navigation Research Program were examined to determine whether the care they received included the following: initiation of antiestrogen therapy in patients with hormone receptor-positive breast cancer; initiation of postlumpectomy radiation therapy; and initiation of chemotherapy in women younger than age 70 years with triple-negative tumors more than 1 cm. This is a secondary analysis of a multicenter quasi-experimental study funded by the National Cancer Institute to evaluate patient navigation. Multiple logistic regression was performed to compare differences in receipt of care between navigated and non-navigated participants.
resultsAmong participants eligible for antiestrogen therapy, navigated participants (n = 380) had a statistically significant higher likelihood of receiving antiestrogen therapy compared with non-navigated controls (n = 381; odds ratio [OR], 1.73; P = .004) in a multivariable analysis. Among the participants eligible for radiation therapy after lumpectomy, navigated participants (n = 255) were no more likely to receive radiation (OR, 1.42; P = .22) than control participants (n = 297).
conclusionWe demonstrate that navigated participants were more likely than non-navigated participants to receive antiestrogen therapy. Future studies are required to determine the full impact patient navigation may have on ensuring that vulnerable populations receive quality care.
Indexed as
Breast NeoplasmsEstrogen Receptor ModulatorsFemaleHealthcare DisparitiesHealth Services AccessibilityHumansMastectomy, SegmentalMiddle AgedPatient NavigationQuality of Health CareEstrogen Receptor Modulators
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.